

57
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: P.A. Billing-Medel

Serial No.: 09/110,720

Filed: July 7, 1998

For: Reagents and Methods Useful for
Detecting Diseases of the Breast

Attorney Docket No.: 6130.US.P1

Examiner: Stephanie Zitomer

Group Art Unit: 1634

Certificate of Hand Delivery:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being hand delivered to service under CFR 1.10 Mail Stop 313(c), Commissioner for Patents, PPO Box 1450, Alexandria, VA 22313-1450 on 5/13/, 2003.



RECEIVED

MAY 13 2003

OFFICE OF PETITIONS

AMENDMENT

Mail Stop 313(c)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

IN THE SPECIFICATION:

On page 11, please delete lines 9-13.

Please amend page 68, lines 4-17 to read as follows:

C. PCR Fragment Analysis. The correct products were verified by size determination using gel electrophoresis with ethidium bromide staining (0.5 µg/ml) and visualized by UV illumination. PCR generated DNA bands of approximately 332 bp, as indicated by DNA size markers, which are indicative of a BS200-specific PCR product in normal breast tissue, breast cancer tissue, were observed, and the MCF7 cell line but not in placental DNA. The BS200-specific band at 332 bp was not observed in the five normal lung and lung cancer tissues tested, nor in the five normal colon and colon cancer tissues tested. Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-16, and fragments or complements thereof, indicates